Atlas Trials

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Clinical trial NCT04205175 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04205175
Sponsor
Children's Hospital Los Angeles
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Hemophilia A With Inhibitor
Start date
2020-07-01
Primary completion
2022-10-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.